Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 200

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

PD-1 Blockade in Advanced Adrenocortical Carcinoma

Open access
Raj, Nitya, Zheng, Youyun, Kelly, Virginia, Katz, Seth S., Chou, Joanne, Do, Richard K.G., Capanu, Marinela, Zamarin, Dmitriy, Saltz, Leonard B., Ariyan, Charlotte E., Untch, Brian R., O'Reilly, Eileen M., Gopalan, Anuradha, Berger, Michael F., Olino, Kelly, Segal, Neil H., Reidy-Lagunes, Diane L. · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: Adrenocortical carcinomas (ACC) are rare and aggressive malignancies with limited treatment options. This study was undertaken to evaluate the immunogenicity of ACC. PATIENTS AND METHODS: Patients with advanced ACC were enrolled in a phase II study to evaluate the clinical activity of pembrolizumab 200 mg every 3 weeks, without restriction on prior therapy. The primary end point was objective response rate. Efficacy was correlated with tumor programmed death-ligand 1 expression, microsatellite-high and/or mismatch repair deficient (MSI-H/MMR-D) status, and somatic and germline genomic correlates. RESULTS: We enrolled 39 patients with advanced ACC and herein report after a median follow-up of 17.8 months (range, 5.4 months to 34.7 months). The objective response rate to pembrolizumab was 23% (nine patients; 95% CI, 11% to 39%), and the disease control rate was 52% (16 patients; 95% CI, 33% to 69%). The median duration of response was not reached (lower 95% CI, 4.1 months). Two of six patients with MSI-H/MMR-D tumors responded. The other seven patients with objective responses had microsatellite stable tumors. The median progression-free survival was 2.1 months (95% CI, 2.0 months to 10.7 months), and the median overall survival was 24.9 months (95% CI, 4.2 months to not reached). Thirteen percent of patients (n = 5) had treatment-related grade 3 or 4 adverse events. Tumor programmed death-ligand 1 expression and MSI-H/MMR-D status were not associated with objective response. CONCLUSION: MSI-H/MMR-D tumors, for which pembrolizumab is a standard therapy, are more common in ACC than has been recognized. In advanced ACC that is microsatellite stable, pembrolizumab provided clinically meaningful and durable antitumor activity with a manageable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.01586

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 200

Metadata

Authors
Raj, N., Zheng, Y., Kelly, V., Katz, S. S., Chou, J., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., Untch, B. R., O'Reilly, E. M., Gopalan, A., Berger, M. F., Olino, K., Segal, N. H., & Reidy-Lagunes, D. L.
Venue
Journal of Clinical Oncology
Published
2020-01-01
Volume
38
Issue
1
Pages
71-80
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2981696991
Cited by
200
References
15
FWCI
20.31
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-1 Blockade in Advanced Adrenocortical Carcinoma. https://app.cochat.ai/papers/10.1200/jco.19.01586
The paper
Raj, N., Zheng, Y., Kelly, V., Katz, S. S., Chou, J., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., Untch, B. R., O'Reilly, E. M., Gopalan, A., Berger, M. F., Olino, K., Segal, N. H., & Reidy-Lagunes, D. L. (2020). PD-1 Blockade in Advanced Adrenocortical Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.01586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.